Merck's CTLA-4 monoclonal antibody enters Phase 3 clinical trial, USD 200 million introduced from Kangfang Biotechnology

Article source: Pharmaceutical Guanlan

On June 16, Kangfang Biological issued a press release stating that the company's CTLA-4 monoclonal antibody quavonlimab (MK-1308) licensed to Merck & Co.

Renal clear cell carcinoma is a common type of renal cell carcinoma (RCC), accounting for about 70% of all RCC cases

Public information shows that MK-1308 was originally discovered by Kangfang Biological

At present, MK-1308 has become an important member of Merck's oncology pipeline

At the 2020 International Association for the Study of Lung Cancer (IASLC) North American Lung Cancer Conference, researchers reported the Phase 1/2 clinical data of MK-1308A.

Screenshot source: Chinadrugtrials

In China, MK-1308A injection has twice obtained the implied license for clinical trials of the Center for Drug Evaluation (CDE) of the State Drug Administration of China, and the proposed development indications include advanced solid tumors and hepatocellular carcinoma

Note: The original text has been deleted

Reference materials:

[1] Kangfang Biotech authorized Merck’s CTLA-4 monoclonal antibody to enter Phase III clinical trials for USD 200 million.

[2]Perets P,Bar J,Rasco DW,et al.